Skip to content

Non-opioid Analgesic Combination With Morphine for Postoperative Analgesia.

Prospective, Controlled Versus Placebo, Randomized, Double-blind Study, Evaluating the Value of Non-opioid Analgesic Combination (Based on Paracetamol, Nefopam, Ketoprofen) for Postoperative Analgesia.

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01882530
Acronym
OCTOPUS
Enrollment
223
Registered
2013-06-20
Start date
2013-07-23
Completion date
2016-01-16
Last updated
2018-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Operative Analgesia

Keywords

Post operative analgesia ;, Paracetamol ;, Ketoprofen ;, Nefopam ;, Morphine

Brief summary

The combination of different analgesic drugs and/or analgesia techniques is part of the standard management of postoperative analgesia. The analysis of the literature reveals a lack of comparison of the associations of non-opioid analgesic (NOA) with morphine for postoperative analgesia. The objectives of this study are : * comparing the morphine sparing effect of different combination of 3 NOA (paracetamol, nefopam, ketoprofen) for postoperative analgesia. * determining whether the morphine-sparing effect is associated with or without a reduction in the incidence of morphine side effects. * evaluating the effects of NOA on postoperative hyperalgesia.

Detailed description

Since the description of the concept of balanced analgesia in the early 90's, the combination of different analgesic drugs and/or analgesia techniques is part of the standard management of postoperative analgesia. A recent survey conducted in France by Fletcher et al. showed that patients often received one or more NOA associated with an opioid. The benefit and risk of the use of opioids associated with NOA were recently reassessed as part of a formal recommendation of experts and detailed in a recent review. The analysis of the literature reveals a lack of comparison of the combinations of NOA with morphine for postoperative analgesia. For example, paracetamol and morphine in combination does not always allow a significant morphine-sparing effect compared with morphine alone and does not reduce the incidence of morphine side effects. A number of definitive answers has therefore yet to be found: Does NOA -morphine association allow an effective morphine-sparing effect? Is there an interest in prescribing several NOAs in association? If yes, what are the most interesting combinations in terms of morphine-sparing effect and safety? Another question concerns the effects of NOA on postoperative hyperalgesia. This hyperalgesia, which results from surgery-related inflammation, is increased by consumption of morphine and not only contributes to the overall experience of postoperative pain but also to the chronicisation of postoperative pain. Since in clinical practice, hyperalgesia can be measured using specific tools (Von Frey filament type), our study will evaluate the anti-hyperalgesic effects of NOA on a subgroup of patients enrolled in the centers used to evaluate nociceptive thresholds. The objectives of this study are : * comparing the morphine sparing effect of different combination of 3 NOA (paracetamol, nefopam, ketoprofen) for postoperative analgesia. * determining whether the morphine-sparing effect is associated with or without a reduction in the incidence of morphine side effects. * evaluating the effects of NOA on postoperative hyperalgesia.

Interventions

DRUGParacetamol
DRUGNefopam
DRUGKetoprofen
DRUGMorphine

Sponsors

Rennes University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults older than 18 years * Receiving scheduled surgery requiring the use of a PCA to treat postoperative pain * Patients with a written informed consent * Patients with a written informed consent for the sub-study on hyperalgesia (patients in the centers concerned) * Affiliate to a social security system

Exclusion criteria

* Allergy to morphine, paracetamol, nefopam or ketoprofen or to any of their excipients * Absorption of morphine and / or NOA within 24 hours before surgery * Absorption of methadone within 48 hours before surgery * History of epilepsy * Renal insufficiency (creatinin clearance \<30 ml / min MDRD) * Hepatic insufficiency * Severe respiratory insufficiency * Pregnancy or breastfeeding women * History of seizures * Symptomatic urethroprostatic disorders * Angle-closure glaucoma * Gastrointestinal, cerebrovascular or other evolving bleedings * Active peptic ulcer or active gastritis * Severe heart failure * History of asthma triggered by taking ketoprofen or similar substances * Disable adult person under guardianship * Use of nitrous oxide during anesthesia protocol

Design outcomes

Primary

MeasureTime frame
Morphine consumption (mg), accumulated over 24 hours, measured by patient controlled analgesia (PCA).Day 1

Secondary

MeasureTime frame
Morphine consumption (mg) measured by patient controlled analgesia (PCA).Day 2, day 3
Incidence of side effects associated with morphine: nausea, vomiting, sedation, urinary retention, pruritus.Day 3
Area of hyperalgesia measured using a von Frey filament expressed in cm2, 48 hours after surgery (sub-study in 3 centers).Day 2
Incidence of chronic pain assessed by a telephone questionnaire 3 months after surgery (sub-study in 3 centers).Month 3
Global satisfaction (measured after treatment)Day 3

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026